Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)
Background: Bevacizumab-awwb (MVASI ® ) was the first U.S. Food and Drug Administration-approved biosimilar to Avastin ® (reference product [RP]) for the treatment of several different types of cancers, including metastatic colorectal cancer (mCRC), an indication approved based on extrapolation. Obj...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-06-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359231182386 |
| _version_ | 1797797848417304576 |
|---|---|
| author | Ran Jin Adesuwa S. Ogbomo Neil A. Accortt Lincy S. Lal Geetanjali Bishi Darcie Sandschafer Jerome H. Goldschmidt |
| author_facet | Ran Jin Adesuwa S. Ogbomo Neil A. Accortt Lincy S. Lal Geetanjali Bishi Darcie Sandschafer Jerome H. Goldschmidt |
| author_sort | Ran Jin |
| collection | DOAJ |
| description | Background: Bevacizumab-awwb (MVASI ® ) was the first U.S. Food and Drug Administration-approved biosimilar to Avastin ® (reference product [RP]) for the treatment of several different types of cancers, including metastatic colorectal cancer (mCRC), an indication approved based on extrapolation. Objectives: Evaluate treatment outcomes in mCRC patients who received first-line (1L) bevacizumab-awwb at treatment initiation or as continuing bevacizumab therapy (switched from RP). Design: A retrospective chart review study. Methods: Adult patients who had a confirmed diagnosis of mCRC (initial presentation of CRC on or after 01 January 2018) and initiated 1L bevacizumab-awwb between 19 July 2019 and 30 April 2020 were identified from the ConcertAI Oncology Dataset. A chart review was conducted to evaluate patient baseline clinical characteristics and effectiveness and tolerability outcomes during the follow-up. Study measures were reported stratified by prior use of RP: (1) naïve patients and (2) switchers (patients who switched to bevacizumab-awwb from RP without advancing the line of therapy). Results: At the end of study period, naïve patients ( n = 129) had a median 1L progression-free survival (PFS) of 8.6 months [95% confidence interval (CI), 7.6–9.9] and a 12-month overall survival (OS) probability of 71.4% (95% CI, 61.0–79.5%). Switchers ( n = 105) had a median 1L PFS of 14.1 months (95% CI, 12.1–15.8) and a 12-month OS probability of 87.6% (95% CI, 79.1–92.8%). During treatment with bevacizumab-awwb, 20 events of interest (EOIs) were reported in 18 naïve patients (14.0%) and 4 EOIs reported in 4 switchers (3.8%), of which the most commonly reported events were thromboembolic and hemorrhagic events. Most EOIs resulted in emergency department visit and/or treatment hold/discontinuation/switch. None of the EOIs resulted in death. Conclusion: In this real-world cohort of mCRC patients who were treated 1L with a bevacizumab biosimilar (bevacizumab-awwb), the clinical effectiveness and tolerability data were as expected and consistent with previously published findings from real-world studies of bevacizumab RP in mCRC patients. |
| first_indexed | 2024-03-13T03:54:33Z |
| format | Article |
| id | doaj.art-1e3bd947becc4f728269150e570d3bc4 |
| institution | Directory Open Access Journal |
| issn | 1758-8359 |
| language | English |
| last_indexed | 2024-03-13T03:54:33Z |
| publishDate | 2023-06-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj.art-1e3bd947becc4f728269150e570d3bc42023-06-22T06:33:23ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592023-06-011510.1177/17588359231182386Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)Ran JinAdesuwa S. OgbomoNeil A. AccorttLincy S. LalGeetanjali BishiDarcie SandschaferJerome H. GoldschmidtBackground: Bevacizumab-awwb (MVASI ® ) was the first U.S. Food and Drug Administration-approved biosimilar to Avastin ® (reference product [RP]) for the treatment of several different types of cancers, including metastatic colorectal cancer (mCRC), an indication approved based on extrapolation. Objectives: Evaluate treatment outcomes in mCRC patients who received first-line (1L) bevacizumab-awwb at treatment initiation or as continuing bevacizumab therapy (switched from RP). Design: A retrospective chart review study. Methods: Adult patients who had a confirmed diagnosis of mCRC (initial presentation of CRC on or after 01 January 2018) and initiated 1L bevacizumab-awwb between 19 July 2019 and 30 April 2020 were identified from the ConcertAI Oncology Dataset. A chart review was conducted to evaluate patient baseline clinical characteristics and effectiveness and tolerability outcomes during the follow-up. Study measures were reported stratified by prior use of RP: (1) naïve patients and (2) switchers (patients who switched to bevacizumab-awwb from RP without advancing the line of therapy). Results: At the end of study period, naïve patients ( n = 129) had a median 1L progression-free survival (PFS) of 8.6 months [95% confidence interval (CI), 7.6–9.9] and a 12-month overall survival (OS) probability of 71.4% (95% CI, 61.0–79.5%). Switchers ( n = 105) had a median 1L PFS of 14.1 months (95% CI, 12.1–15.8) and a 12-month OS probability of 87.6% (95% CI, 79.1–92.8%). During treatment with bevacizumab-awwb, 20 events of interest (EOIs) were reported in 18 naïve patients (14.0%) and 4 EOIs reported in 4 switchers (3.8%), of which the most commonly reported events were thromboembolic and hemorrhagic events. Most EOIs resulted in emergency department visit and/or treatment hold/discontinuation/switch. None of the EOIs resulted in death. Conclusion: In this real-world cohort of mCRC patients who were treated 1L with a bevacizumab biosimilar (bevacizumab-awwb), the clinical effectiveness and tolerability data were as expected and consistent with previously published findings from real-world studies of bevacizumab RP in mCRC patients.https://doi.org/10.1177/17588359231182386 |
| spellingShingle | Ran Jin Adesuwa S. Ogbomo Neil A. Accortt Lincy S. Lal Geetanjali Bishi Darcie Sandschafer Jerome H. Goldschmidt Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb) Therapeutic Advances in Medical Oncology |
| title | Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb) |
| title_full | Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb) |
| title_fullStr | Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb) |
| title_full_unstemmed | Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb) |
| title_short | Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb) |
| title_sort | real world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar bevacizumab awwb |
| url | https://doi.org/10.1177/17588359231182386 |
| work_keys_str_mv | AT ranjin realworldoutcomesamongpatientswithmetastaticcolorectalcancertreatedfirstlinewithabevacizumabbiosimilarbevacizumabawwb AT adesuwasogbomo realworldoutcomesamongpatientswithmetastaticcolorectalcancertreatedfirstlinewithabevacizumabbiosimilarbevacizumabawwb AT neilaaccortt realworldoutcomesamongpatientswithmetastaticcolorectalcancertreatedfirstlinewithabevacizumabbiosimilarbevacizumabawwb AT lincyslal realworldoutcomesamongpatientswithmetastaticcolorectalcancertreatedfirstlinewithabevacizumabbiosimilarbevacizumabawwb AT geetanjalibishi realworldoutcomesamongpatientswithmetastaticcolorectalcancertreatedfirstlinewithabevacizumabbiosimilarbevacizumabawwb AT darciesandschafer realworldoutcomesamongpatientswithmetastaticcolorectalcancertreatedfirstlinewithabevacizumabbiosimilarbevacizumabawwb AT jeromehgoldschmidt realworldoutcomesamongpatientswithmetastaticcolorectalcancertreatedfirstlinewithabevacizumabbiosimilarbevacizumabawwb |